|
| 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Basic information |
Product Name: | 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- | Synonyms: | 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-;MS140;XY028-140;CDK6,CDK4,PROTACs,anticancer,XY028140,Cyclin dependent kinase,XY-028-140,XY028 140,CDK,inhibit,Inhibitor;XY028-140 (MS140) | CAS: | 2229974-83-6 | MF: | C39H40N10O7 | MW: | 760.8 | EINECS: | | Product Categories: | | Mol File: | 2229974-83-6.mol | ![1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Structure](CAS/20210305/GIF/2229974-83-6.gif) |
| 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Chemical Properties |
density | 1.482±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 5.56 mg/mL (7.31 mM; ultrasonic and warming and heat to 60°C) | form | Solid | pka | 10.74±0.40(Predicted) | color | White to yellow |
| 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Usage And Synthesis |
Biological Activity | XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].
A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 μμ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 μμ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1]. | References | [1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1. |
| 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Preparation Products And Raw materials |
|